1. TP53 mutant status significantly associated with bone marrow blast clearance after treatment with decitabine in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). Evidence Rating Level: 2 (good) Study Rundown: AML and MDS are clonal myeloid neoplasms. Decitabine is a hypomethylating agent that promotes re-expression of tumor suppressor genes, and is commonly
↧